Press Release Details

Upgrade your cell-free DNA experience

Know more. Learn how we have improved our Innatal® Prenatal Screen.

Progenity is dedicated to continuous product improvement. We have upgraded the Innatal Prenatal screen with the latest sequencing technology and improved chemistry.

In-depth verification and validation testing of the Innatal assay, using >1000 samples, was conducted as prescribed by multiple peer-reviewed guidelines.1,2,3

What did we find?

The Innatal Prenatal Screen is:

Precise – Agreement of >99% for repeatability and reproducibility4

Accurate – High concordance with known clinical outcomes4

Sensitive – Proven to identify affected fetuses with >99% sensitivity4

Specific – Proven to rule-out unaffected fetuses with >99% specificity4


PolyValidation_Thumbnail_0.jpgData Summary Sheet

A detailed summary of our verification and validation results.

Download the data summary sheet >







Have questions?

Dive deeper on how this data uniquely impacts your practice by contacting us. We’ll give you direct access to our lab team.

Email us >







  1. Jennings et al. Recommended principles and practices for validating clinical molecular pathology tests. Arch Pathol Lab Med. 2009;133(5):743-55.
  2. Lacbawan et al. Verification of performance specifications of a molecular test: cystic fibrosis carrier testing using the Luminex liquid bead array. Arch Pathol Lab Med. 2012;136(1):14-9.
  3. Rehm et al. ACMG clinical laboratory standards for next-generation sequencing. Genet Med. 2013;15(9):733-47.
  4. Progenity, Inc. Data on file.